Pharmacy benefit managers (PBMs) should be stopped from usurping 340B drug discounts from HIV/AIDS clinics and other safety-net providers, Ryan White Clinics for 340B Access (RWC-340B) told the U.S. Federal Trade Commission (FTC) last week.
RWC-340B asked the commission for protection from PBMs in an April 22 letter. The FTC in late February invited the public to comment on how large, vertically integrated PBMs are affecting drug affordability and access. It did so days after an unexpected 2-2 tie vote doomed Chair Lina Khan’s proposal that the commission investigate PBMs commercial practices. The deadline for comments is May 25. Drug manufacturers and other stakeholders are expected to submit comments as well.
Pharmacy benefit managers (PBMs) should be stopped from usurping 340B drug discounts from HIV/AIDS clinics and other safety-net providers, Ryan White Clinics for 340B Access (RWC-340B) told the U.S. Federal Trade Commission (FTC) last week.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
